| Wednesday, February 13, 2019 |
SESSION I - Diabetic Retinopathy |
|
| |
|
|
| 4:25 p.m |
Multiethnic Genome-Wide Association Study of Diabetic Retinopathy |
Lucia Sobrin |
| 4:29 p.m |
DRGen Study: Novel Genetic Variants in Extreme and Advanced (Proliferative)
Phenotypes of Diabetic Retinopathy |
Arup Das |
| 4:33 p.m. |
Risk Factors for Blindness in Patients With Diabetic Retinopathy: Lessons from
the AAO IRIS® Registry |
Rahul Khurana |
| 4:37 p.m. |
Integrating Diabetic Eye Screening in a Haemodialysis Clinic |
Tunde Peto |
| 4:41 p.m. |
Discussion of Previous Four Papers |
|
| 4:45 p.m. |
Is Cataract Surgery a Risk Factor for the Incidence and Progression of Age-Related
Macular Degeneration and Diabetic Retinopathy? |
Tien Wong |
| 4:54 p.m |
Diabetic Retinopathy Outcomes in Untreated Fellow Eyes of Patients Receiving
Ranibizumab in the RIDE/RISE Trials: The Road Less Traveled |
Sophie Bakri |
| 5:03 p.m. |
Patients Ultra-Responsive to Ranibizumab: Rates of >=4-Step Improvement in
Diabetic Retinopathy Severity in DRCR.net Protocol S |
Sunir Garg |
| 5:12 p.m. |
Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
with Intravitreal Aflibercept Injection: Results from the Phase 3 PANORAMA Study |
David Brown |
| 5:21 p.m. |
Optical Coherence Tomography Angiography Confirms that Intravitreal Anti-Vascular
Endothelial Growth Factor Can Diminish Signs of Diabetic Retinopathy Without
Reducing Non-Perfusion |
Ramin Tadayoni |
| 5:30 p.m |
Post Hoc Exploratory Analysis of Humphrey Visual Field Changes Through Five
Years in Eyes with Proliferative Diabetic Retinopathy |
Michael Elman |
| 5:39 p.m |
Anti-Vascular Endothelial Growth Factor Therapy and Risk of Traction Retinal
Detachment in Eyes with Proliferative Diabetic Retinopathy: Post Hoc Analysis
of Five DRCR.net Randomized Clinical Trials |
Justin Gottlieb |
| 5:50 p.m. |
Introduction and Presentation of the Lawrence J. Singerman Medal
– Morton F. Goldberg, MD, FACS |
|
| 5:53 p.m. |
Award Recipient – Matthew D. Davis, MD (posthumous) |
|
| |
|
|
| |
SESSION II - Oncology 1 |
|
| |
|
|
| 6:00 p.m. |
Intravitreal and Intra-Arterial Chemotherapy Drug Discovery Using a
Rabbit Model: Toxicity and Efficacy of Novel Compounds in Vivo |
Anthony Daniels |
| 6:04 p.m. |
Impact of Quantitative Genetic Ancestry on Precision Medicine in Uveal Melanoma |
J. William Harbour |
| 6:08 p.m. |
Discussion of Previous Two Papers |
|
| |
|
|
| |
SESSION III - Imaging |
|
| |
|
|
| 6:15 p.m |
Ultra-Widefield Swept-Source OCT Imaging of Posterior Vitreous in Eyes with
High Myopia |
Kyoko Ohno-Matsui |
| 6:24 p.m. |
Macular Pigment in Multiple Sclerosis |
Giovanni Staurenghi |
| 6:33 p.m |
Quantifying Organelles Serving as Signal Sources for Imaging of the Human
Retinal Pigment Epithelium (RPE), via Volume Electron Microscopy |
Christine Curcio |
| 6:42 p.m |
Hyperspectral Autofluorescence (AF) Imaging for Detection of Drusen and
Sub Retinal Pigment Epithelium (subRPE) deposits |
R. Theodore Smith |
| 6:46 p.m. |
Age-Related Changes in Autofluorescent (AF) Granules Accumulation of
the Human Retinal Pigment Epithelium (RPE) |
Thomas Ach |
| 6:50 p.m. |
Diabetic Retinopathy Severity Level Assessment: Comparison of Seven-field
Fundus Photographs to Ultrawide-Field Imaging |
Barbara Blodi |
| 6:54 p.m. |
Quantitative Comparison of Retinal Pixel Area Imaged by Ultra-Wide
Field Fundus Cameras |
Ajay Kuriyan |
| 6:58 p.m. |
Retinal Vascular Geometry and the Subsequent Risk of Diabetes |
Gavin Tan |
| 7:02 p.m. |
Discussion of Previous Five Papers |
|
| 7:07 p.m. |
Computational Fluid Dynamics Modeling of Diabetic Microaneurysms Identifies
Blood Flow Parameters Associated with Clot Presence and Local Neural
Retinal Disorganization |
Jennifer Sun |
| 7:16 p.m. |
Topographic Variations of Choroidal Thickness in Healthy Eyes on Swept Source
Optical Coherence Tomography |
Alain Gaudric |
| 7:20 p.m. |
Remodeling of Macular Vortex Veins in Pachychoroid Neovasculopathy |
Shoji Kishi |
| 7:24 p.m. |
Dynamic Changes in Choroidal Conditions During Anti-Vascular Endothelial
Growth Factor Therapy in Polypoidal Choroidal Vasculopathy |
Yoko Ozawa |
| 7:28 p.m. |
Discussion of Previous Three Papers |
|
| |
|
|
| 7:32 p.m. |
Adjourn |
|
| |
|
|
| Thursday, February 14, 2019 |
SESSION IV - OCT Angiography |
|
| |
|
|
| 7:30 a.m. |
Longitudinal Analaysis of Foveal Microvasculature Using OCT Angiography after
Rhegmatogenous Retinal Detachment Surgery |
Seung-Young Yu |
| 7:39 a.m. |
How Abnormal is this FAZ? - Easier Detection of Diabetic FAZ Enlargement
Comparing En Face OCT Vascular Patterns to OCT Angiography |
Richard Rosen |
| 7:46 a.m. |
Quantitative OCT Angiography Analysis for Classification and Staging of
Non-Proliferative Diabetic Retinopathy |
Jennifer Lim |
| 7:53 a.m. |
Discussion of Previous Two Papers |
|
| 7:57 a.m. |
4D OCTA: Time-Resolved OCTA Can Visualize Chorioretinal Hemodynamics |
Nadia Waheed |
| 8:06 a.m. |
Choriocapillaris Flow Impairment Surrounding Geographic Atrophy Correlates
with Disease Progression |
SriniVas Sadda |
| 8:13 a.m |
Relationship Between Choriocapillaris Flow Deficits Around Geographic
Atrophy and Enlargement Rates Based on Swept Source OCT Imaging |
Philip Rosenfeld |
| 8:20 a.m. |
Discussion of Previous Two Papers |
|
| 8:24 a.m. |
New Proposal for the Pathophysiology of Type 3 Neovascularization as
Based on Multimodal Imaging Findings |
Richard Spaide |
| 8:33 a.m |
Sensitivity of OCT Angiography in the Detection of Choroidal Neovascularization
in Wet AMD in Relation to Anatomical Features on SDOCT |
Aude Ambresin |
| 8:37 a.m. |
3D Volumetric Analysis of Pigment Epithelial Detachment Progression in
Neovascular AMD using En Face OCT Angiography |
David Sarraf |
| 8:44 a.m. |
Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is
Associated With Therapy Response in Wet Age-Related Macular Degeneration |
Amani Fawzi |
| 8:51 a.m. |
Discussion of Previous Three Papers |
|
| 8:55 a.m. |
Introduction and Presentation of the Young Investigator Lecture and Award
– Eric H. Souied, MD, PhD |
|
| 8:58 a.m. |
Award Recipient and Lecture – Giuseppe Querques, MD, PhD |
|
| 9:01 a.m. |
Discussion and Questions |
|
| |
|
|
| |
SESSION V - Neovascular AMD I |
|
| |
|
|
| 9:15 a.m. |
Prospective Trial Comparing Intravitreal Aflibercept Injection (IAI) Using a Modified
Treat-and-Extend (T&E) to Fixed Bi-Monthly Protocol for PCV: 6-Month Outcomes |
Gemmy Cheung |
| 9:24 a.m. |
Ten-Year Treatment Outcome of Polypoidal Choroidal Vasculopathy Using
Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor |
Won Ki Lee |
| 9:33 a.m. |
A Cost-Utility/Cost-Benefit Analysis of Bevacizumab, Ranibizumab & Aflibercept
Monotherapy for Treating Neovascular Age-Related Macular Degeneration (NVAMD) |
Gary Brown |
| 9:37 a.m. |
Association Between Early Vision-Related Quality of Life Outcomes and Anatomic
Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD):
A Post-Hoc Analysis of VIEW Trials |
Michael Singer |
| 9:41 a.m |
Higher-Order Optical Coherence Tomography (OCT) Fluid Burden Assessment: Analysis
From OSPREY Matched Phase |
Justis Ehlers |
| 9:45 a.m. |
Discussion of Previous Three Papers |
|
| 9:48 a.m. |
Intravitreal Aflibercept in a Routine Treat and Extend Regimen in Treatment-Naïve Wet
AMD Patients: Prefinal 1-Year Outcome Data of the ASTERIA Study |
Stephan Michels |
| 9:57 a.m. |
Brolucizumab Versus Aflibercept for Neovascular AMD: 48-Week Expanded Fluid
Analyses from the HAWK and HARRIER Studies |
Peter Kaiser |
| 10:06 a.m |
Intravitreal (IVT) Delivery of a Novel Depot Formulation of Sunitinib (GB-102) in
Patients With nAMD: Results of a Phase 1 First-in-Human Study |
Pravin Dugel |
| 10:15 a.m. |
Port Delivery System With Ranibizumab (PDS) in Neovascular AMD: How Ladder
Phase 2 Results Informed Archway Phase 3 Design |
Dennis Marcus |
| 10:24 a.m. |
Phase I/II Randomized Study of Proton Beam with Anti-VEGF For Exudative
Age-Related Macular Degeneration: Long-Term Results |
Susanna Park |
| |
|
|
| 10:30 a.m. |
Break |
|
| |
|
|
| |
SESSION VI - Deep Learning / Artificial Intelligence |
|
| |
|
|
| 10:50 a.m. |
Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color
Fundus Photographs |
Anthony Adamis |
| 10:59 a.m. |
Deep Generative Models Creating High-Resolution Synthetic Retinal Images and
Relevance to Humans and Machines |
Neil M. Bressler, |
| 11:08 a.m. |
DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-Based
Age-Related Macular Degeneration Severity from Color Fundus Photographs. |
Emily Chew |
| 11:17 a.m. |
Deep Learning in the Prediction of AMD Disease Progression |
Ursula Schmidt-Erfurth |
| 11:26 a.m. |
Automated Segmentation of Lesions in Neovascular AMD |
Hyung Chan Kim |
| 11:30 a.m. |
Prognostic Factors in Patients with Neovascular AMD or PCV from Clinical and OCT
Parameters using a Convolutional Neural Network |
Hyewon Chung |
| 11:34 a.m. |
Artificial Intelligence for Morphology-Based Function Prediction in Neovascular
Age-Related Macular Degeneration |
Steffen Schmitz-Valckenberg |
| 11:38 a.m. |
Robustness of an Autonomous AI System for Detection of Diabetic Retinopathy |
Michael Abramoff |
| 11:42 a.m. |
Artificial Intelligence Deep Learning System for Measurement of Retinal
Vascular Caliber |
Carol Cheung |
| 11:46 a.m |
Discussion of Previous Five Papers |
|
| 11:50 a.m. |
Introduction and Presentation of the J. Donald M. Gass Medal – Carol L. Shields,
MD, and Emily Y. Chew, MD |
|
| 11:53 a.m. |
Anthony AdamisAward Recipient – Usha Chakravarthy, MBBS, MD, PhD |
|
| |
|
|
| |
SESSION VII - Dry AMD |
|
| |
|
|
| 12:00 p.m. |
Longitudinal Changes in Rod Function in Intermediate Age-Related Macular
Degeneration With and Without Reticular Pseudodrusen |
Chi Luu |
| 12:04 p.m. |
Classification of Intermediate Age-Related Macular Degeneration by Short-Term
Risk for Atrophy on Spectral Domain Optical Coherence Tomography |
Eleonora Lad |
| 12:08 p.m. |
The 9-Step Minnesota Grading System: A Model to Study Disease Pathogenesis |
Timothy Olsen |
| 12:12 p.m. |
Müller Cells and Choriocapillaris in the Pathogenesis of Geographic Atrophy
Secondary to Age-Related Macular Degeneration |
Elisabetta Pilotto |
| 12:16 p.m. |
Taurocholic Acid Protects Against Age-Related Macular Degeneration in In Vitro Models |
Milam Brantley |
| 12:20 p.m. |
Discussion of Previous Five Papers |
|
| 12:25 p.m. |
Choroidal Vascular Changes in Atrophic AMD: Relationship with Disease
Stage and ARMS2 Genotype |
Robert Mullins |
| 12:34 p.m. |
Kamuvudines for Geographic Atrophy |
Jayakrishna Ambati |
| 12:43 p.m. |
The Fate and Prognostic Implications of Cholesterol Crystals in Non-Neovascular
Age-Related Macular Degeneration |
K. Bailey Freund |
| 12:52 p.m. |
Cuticular Drusen: The Nature of Phenotype 3 |
Lawrence Yannuzzi |
| 1:01 p.m. |
Subthreshold Nanosecond Laser to Slow Progression of Intermediate Age-Related
Macular Degeneration: The LEAD Trial Secondary Outcomes |
Robyn Guymer |
| 1:10 p.m. |
Photovoltaic Restoration of Central Vision in Patients with Geographic Atrophy |
José-Alain Sahel |
| |
|
|
| 1:15 p.m |
Young Member Mentor Lecture Program |
|
| |
|
|
| Friday, February 15, 2019 |
|
|
| |
|
|
| 7:00 a.m. |
Business Meeting |
|
| |
|
|
| |
SESSION VIII - Neovascular AMD II |
|
| |
|
|
| 7:50 a.m. |
Topical Inhibition of Runx1 Reduces Choroidal Neovascularization in Mice |
Leo Kim |
| 7:54 a.m. |
Anti-VEGF Monotherapy for Thick Submacular Hemorrhage Associated with Retinal
Pigment Epithelial Detachment in Age-Related Macular Degeneration |
Jeffrey Gross |
| 7:58 a.m. |
Time to Maximum Response in Eyes with Neovascular AMD Treated with Ranibizumab |
Demetrios Vavvas |
| 8:02 a.m. |
Comparison of Intravitreal Silicone Oil Microdroplet Following Multiple Bevacizumab,
Ranibizumab and Aflibercept Injections |
John Thompson |
| 8:06 a.m |
Discussion of Previous Four Papers |
|
| 8:10 a.m |
Antagonism of Mineralocorticoids Inhibits Choroidal Neovascularization: Implication
for Wet AMD |
Francine Behar-Cohen |
| 8:19 a.m |
Human Plasma Metabolomics in Age-Related Macular Degeneration
– Meta-Analysis of Two Distinct Cohorts |
Joan Miller |
| 8:28 a.m. |
Is Drier Really Better in Neovascular Age-Related Macular Degeneration? |
Nancy Holekamp |
| 8:37 a.m |
A “Real World” Analysis of Visual Acuity Outcomes in 49,485 Eyes Receiving
Anti-Vascular Endothelial Growth Factor Therapy for Neovascular AMD |
Thomas Ciulla |
| 8:46 a.m |
Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis
According to Baseline Visual Acuity |
Judy Kim |
| 8:55 a.m. |
Analysis of Anti-VEGF Injection Claims Data in Medicare Beneficiaries Following CATT Trial |
Paul Sternberg, Jr |
| |
|
|
| |
SESSION IX - Vitreo-Retinal Surgery |
|
| |
|
|
| 9:05 a.m. |
Central Retinal Artery Occlusion on Postoperative Day One after Vitreoretinal Surgery |
Harry Flynn |
| 9:09 a.m. |
Rotation in Retinal Nerve Fiber Layer Peak after Epiretinal Membrane Removal |
Hyeong Gon Yu |
| 9:13 a.m. |
Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study:
Five-Year Findings |
Stephen Kim |
| 9:17 a.m. |
Posterior Vitreous Mobility Delineated by Tracking of Optical Coherence
Tomography Images in Eyes with Macular Holes |
Keisuke Mori |
| 9:21 a.m. |
Clinical Characteristics, Risk Factors, and Surgical Outcomes of a Secondary
Macular Hole after Vitrectomy |
Min Kim |
| 9:25 a.m. |
Discussion of Previous Five Papers |
|
| 9:29 a.m. |
Comparative Study of Peeled Internal Limiting Membrane (ILM) Reposition and
ILM Peeling in Idiopathic Macular Hole: A Randomized-Control Trial |
Peiquan Zhao |
| 9:38 a.m. |
First Failed Macular Hole Surgery or Reopening of a Previously Closed Hole:
Do we Gain by Re-Operating? – A Systematic Review and Meta Analysis |
Noemi Lois |
| 9:47 a.m. |
Connecting the Surgeon to OCT Image Guidance for Vitreoretinal Surgery |
Cynthia Toth |
| 9:56 a.m. |
Placing the Surgeon in the Center - Placing the Surgeon in the Center -
A Novel 3D Visualization Platform for Retina Surgery Providing Transparent
Display, Data Overlay and Guidance |
Anat Loewenstein |
| 10:05 a.m. |
Introduction and Presentation of the Paul Henkind Memorial Lecture and Award
- Sophie J. Bakri, MD |
|
| 10:08 a.m. |
Paul Henkind Memorial Lecture and Award - Jose S. Pulido, MD, MS, MBA, MPH |
|
| |
|
|
| 10:25 a.m. |
Break |
|
| |
|
|
| |
SESSION X - Diabetic Macular Edema |
|
| |
|
|
| 10:45 a.m. |
Müller Cells Activity is Restored and Retinal Inflammation Reduced by Subthreshold
Micropulse Laser Treatment of Human Diabetic Macular Edema |
Edoardo Midena |
| 10:49 a.m. |
OCT Angiography Detects Early Microvascular Changes after Subthreshold
Micropulse Laser in Diabetic Macular Edema |
Stela Vujosevic |
| 10:53 a.m. |
Two-year Outcomes of Ranibizumab Treatment for Diabetic Macular Edema.
Data from the Fight Retinal Blindness! Project |
Daniel Barthelmes |
| 10:57 a.m. |
Vision Threatening Complications in Patients with Diabetic Macular Edema:
A Post Hoc Analysis from the VISTA and VIVID Trials |
Ivan Suner |
| 11:01 a.m. |
Discussion of Previous Four Papers |
|
| 11:05 a.m. |
A 12-month Prospective Study to Evaluate the Efficacy of Treat and Extend Regimen (T&E)
of Intravitreal Aflibercept as a Second-Line Treatment for Diabetic Macular Edema (TADI Study) |
Itay Chowers |
| 11:14 a.m. |
Observation Versus Treatment in Diabetic Macular Edema with Very Good Visual Acuity
– The OBTAIN Study |
Adrian Fung |
| 11:23 a.m. |
Relationship between Change in Visual Acuity and Change in Retinal Thickness during
Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept,
Bevacizumab or Ranibizumab |
Mathew MacCumber |
| 11:27 a.m. |
Visual Acuity with Habitual Correction on an Early Treatment Diabetic Retinopathy
Study (ETDRS) Chart vs. Protocol Refraction on an Electronic ETDRS Chart in Eyes
with Diabetic Macular Edema |
Susan Bressler |
| 11:31 a.m. |
Long-Term Intraocular Pressure Outcomes in Patients Receiving the 0.2 ug/day Fluocinolone
Acetonide Intravitreal Implant |
Daniel Roth |
| 11:35 a.m. |
Discussion of Previous Three Papers |
|
| 11:39 a.m. |
Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for
Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE Trial |
Charles Wykoff |
| 11:48 a.m. |
Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Evidence for Increased Durability
from the BOULEVARD Phase 2 Trial for Diabetic Macular Edema |
Caroline Baumal |
| |
|
|
| |
SESSION XI - Pediatric Retina and Inherited Retinal Diseases |
|
| |
|
|
| 12:00 p.m. |
Fluorescein Angiography Findings in Infants Treated With Intravitreal Bevacizumab
for Retinopathy of Prematurity |
G. Baker Hubbard, III |
| 12:09 p.m. |
An Interesting Family with Achromatopsia |
J. Timothy Stout |
| 12:18 p.m. |
Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with
Microperimetry in Patients with Stargardt Disease – The SMART Study |
Hendrik Scholl |
| 12:27 p.m. |
Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt
Disease (STGD1): Design of a Clinical Trial Assessing a Novel Treatment and
Primary Outcome Measure |
Christine Kay |
| 12:36 p.m. |
Extracellular Matrix Disorders and Inherited Retinal Dystrophies |
Isabelle Meunier |
| 12:40 p.m. |
RDH12 Disease: A Severe Central Retinal Degeneration with Relatively
Spared Rod Function |
Tomas Aleman |
| 12:44 p.m. |
Disease Stage Classification of Choroideremia for Clinical Treatment Trials
and Clinical Practice |
Peter Francis |
| 12:48 p.m. |
Optical Coherence Tomography Angiography Assessment of Neurovascular
Damage as Biomarker of Progression in Best Disease |
Maurizio Battaglia Parodi |
| 12:52 p.m. |
Discussion of Previous Four Papers |
|
| 1:00 p.m. |
Introduction and Presentation of the Arnall Patz Medal – Gregory S. Hageman, MD, PhD |
|
| 1:03 p.m. |
Award Recipient – Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO |
|
| |
|
|
| 1:15 p.m. |
Adjourn |
|
| |
|
|
| Saturday, February 16, 2019 |
SESSION XII - Neuroprotection, Gene Therapy, Regenerative Medicine |
|
| |
|
|
| 7:30 a.m |
VMD2 Promoter Shows Optimal Specificity and Expression of Protective
Rap1a in Retinal Pigment Epithelium |
Mary Elizabeth Hartnett |
| 7:39 a.m. |
A New Approach to Ocular Gene Therapy: Evaluation of Suprachoroidal
Administration of Non-Viral DNA Nanoparticles in a Rabbit Model |
Szilard Kiss |
| 7:48 a.m. |
Progress Toward Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa |
Edwin Stone |
| 7:57 a.m. |
Change in Legal Blindness Status During the Phase 3 Voretigene Neparvovec-rzyl
Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease |
Julia Haller |
| 8:06 a.m. |
Optogenetics for Vision Restoration |
Sai Chavala |
| 8:15 a.m. |
Intraoperative Optical Coherence Tomographic Findings in Patients
Undergoing Ocular Gene Therapy Surgery |
Andreas Lauer |
| 8:19 a.m. |
Surgical Implantation and In-Vivo Degradation of Fibrin Scaffolds within the Subretinal Space |
Raymond Iezzi |
| 8:23 a.m. |
In-Vivo Imaging of Cone Photoreceptor Transplantation |
Mandeep Singh |
| 8:27 a.m. |
Neuroprotective Role of Hexokinase 2 in Photoreceptor Survival |
Cagri Besirli, |
| 8:31 a.m. |
Discussion of Previous Four Papers |
|
| 8:35 a.m. |
Introduction and Presentation of the W. Richard Green Lecture and Award
– Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO |
|
| 8:38 a.m. |
W. Richard Green Lecture and Award – Paul S. Bernstein, MD, PhD |
|
| 8:58 a.m. |
Introduction and Presentation of the Evangelos S. Gragoudas Lecture
and Award – Neil M. Bressler, MD |
|
| 9:01 a.m. |
Evangelos S. Gragoudas Recipient Lecture and Award – Daniel Shu Wei Ting, MD, PhD |
|
| 9:05 a.m. |
Introduction and Presentation of the Lawrence J. Singerman Medal – Emily Y. Chew, MD |
|
| 9:08 a.m. |
Award Recipient – Maureen G. Maguire, PhD, FARVO |
|
| |
|
|
| |
SESSION XIII - Oncology 2 |
|
| |
|
|
| 9:15 a.m. |
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) of Retinoblastoma Tumors |
Jasmine Francis |
| 9:19 a.m. |
Discussion of Previous Paper |
|
| 9:21 a.m. |
Follow the Nevus: The Cost-Utility of Screening for Growth of Choroidal Nevi |
William Smiddy |
| 9:30 a.m. |
Small Choroidal Melanoma Managed by Plaque Radiotherapy in 1780 Cases:
Visual Outcome and Millimeter Incremental Risk for Metastasis |
Carol Shields |
| 9:39 a.m. |
Clinical Features and Survival Outcome of 1111 Patients with Choroidal
Metastasis Based on Primary Tumor Origin |
Jerry Shields |
| 9:48 a.m. |
Outcomes after Proton Irradiation for Patients Who are Eligible for
Investigational AU-011 Treatment |
Evangelos Gragoudas |
| 9:57 a.m. |
Aflibercept for Radiation Maculopathy (ARM Study): A Prospective, Randomized
Clinical Study with 2 year Outcome Analysis |
Timothy Murray |
| |
|
|
| 10:10 a.m. |
Break |
|
| |
|
|
| |
SESSION XIV - Other Macular Diseases |
|
| |
|
|
| 10:30 a.m. |
Longitudinal Changes in Eyes with Hydroxychloroquine Retinal Toxicity |
Catherine Cukras |
| 10:39 a.m. |
Topographic OCT Shows Limited Anatomic Recovery from Early
Hydroxychloroquine Retinopathy |
Michael Marmor |
| 10:48 a.m. |
Association Between Industry Payments and Scholarly Impact Amongst
Retina Specialists and Ophthalmologists |
Ron Adelman |
| 10:52 a.m. |
Anti-Enolase Drusen as a Subtype of Autoimmune Retinopathy |
Susumu Ishida |
| 10:56 a.m. |
Genes Associated with the Clinical Characteristics of Central Serous
Chorioretinopathy |
Akitaka Tsujikawa |
| 11:00 a.m. |
Discussion of Previous Three Papers |
|
| 11:03 a.m. |
Chronic Obstructive Sleep Apnea and Central Serous Chorioretinopathy:
A Significant Association and Possible Mechanism |
Steven Schwartz |
| 11:12 a.m. |
Bruch’s Membrane and Myopic Axial Elongation |
Jost Jonas |
| 11:21 a.m. |
Exploring Retinal Mechanisms in Myopia: Photopic Electroretinogram
Parameters and a Common Myopia Susceptibility Variant |
Omar Mahroo |
| 11:25 a.m. |
Digital Quantification of Metamorphopsia in Patients With Macular Disease:
A Pilot Study |
Andrew Moshfeghi |
| 11:29 a.m. |
Discussion of Previous Two Papers |
|
| |
|
|
| |
SESSION XV - Retinal Venous Occlusive Disease |
|
| |
|
|
| 11:32 a.m. |
Supernormal Flicker ERGs in Eyes with Central Retinal Vein Occlusion:
Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent |
Mineo Kondo |
| 11:36 a.m. |
A Novel Contrast Sensitivity Testing Device as a New Clinical Endpoint for
Retinal Vein Occlusion |
John Miller |
| 11:40 a.m |
Discussion of Previous Two Papers |
|
| 11:42 a.m. |
Patient-Reported Visual Function Outcomes after Anti-VEGF Therapy for
Macular Edema due to CRVO or HRVO: Results from the SCORE2 Trial |
Ingrid Scott |
| 11:51 a.m. |
SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for
Macular Edema due to Retinal Vein Occlusion in the SHORE Study |
Glenn Yiu |
| 12:00 p.m. |
Long Term Outcomes of Eyes with Macular Edema Secondary to CRVO
Treated with Intravitreal Bevacizumab. Real Life Experience of the
Pan American Collaborative Retina Study (PACORES) Group |
Lihteh Wu |
| 12:09 p.m. |
Re-packaging Bevacizumab in 2-mL Glass Vials for Prolonged Sterility, Stability and Bio-activity |
Michael Ip |
| |
|
|
| |
SESSION XVI - Uveitis |
|
| |
|
|
| 12:20 p.m. |
Polymerase Chain Reaction in the Diagnosis of Toxoplasma Gondii
Chorioretinitis |
Thomas Albini, |
| 12:24 p.m. |
Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on
Initiating Antitubercular Therapy in Serpiginous Like Choroiditis |
Vishali Gupta |
| 12:28 p.m. |
Post-Surgical Versus Post-Intravitreal Injection Endophthalmitis:
Changing Patterns in Causative Flora |
Matthew Simunovic |
| 12:32 p.m. |
Discussion of Previous Three Papers |
|
| 12:34 p.m. |
Effect of Intravitreal Sirolimus on Visual Acuity in Subjects with Active Non-infectious
Uveitis of the Posterior Segment of the Eye: Results of the SAKURA Program |
Brian Joodeph |
| 12:43 p.m. |
Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone
Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs.
INTravitreal Corticosteroids for Uveitic Macular |
Michael Altaweel |
| 12:52 p.m. |
Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of
Macular Edema in a Majority of Uveitis Patients: Results of the AZALEA,
DOGWOOD, and PEACHTREE Studies |
Seenu Hariprasad |
| 1:01 p.m. |
Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in
Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study |
Steven Yeh |
| |
|
|
| 1:04 p.m. |
Closing Remarks |
|
| |
|
|
| 1:10 p.m. |
Adjourn |
|
1075